Abstract
Nanoparticles (NPs) have distinct pharmacokinetic (PK) properties and can potentially improve the absorption, distribution, metabolism, and elimination (ADME) of small-molecule drugs loaded therein. Owing to the unwanted toxicities of anticancer agents in healthy organs and tissues, their precise delivery to the tumor is an essential requirement. There have been numerous advancements in the development of nanomedicines for cancer therapy. Physiologically based PK (PBPK) models serve as excellent tools for describing and predicting the ADME properties and the efficacy and toxicity of drugs, in combination with pharmacodynamic (PD) models. The recent preliminary application of these modeling approaches to NPs demonstrated their potential benefits in research and development processes relevant to the ADME and pharmacodynamics of NPs and nanomedicines. Here, we comprehensively review the pharmacokinetics of NPs, the developed PBPK models for anticancer NPs, and the developed PD model for anticancer agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed E, Hashish A, Rihan FA (2012) On fractional order cancer model. J Fract Calc Appl 3:1–6
Ande A, Vaidya TR, Tran BN, Vicchiarelli M, Brown AN, Ait-Oudhia S (2018) Utility of a novel three-dimensional and dynamic (3DD) cell culture system for PK/PD studies: evaluation of a triple combination therapy at overcoming anti-HER2 treatment resistance in breast cancer. Front Pharmacol 9:403. https://doi.org/10.3389/fphar.2018.00403
Angstmann CN, Donnelly IC, Henry BI (2013) Continuous time random walks with reactions forcing and trapping. Math Model Nat Phenom 8:17–27. https://doi.org/10.1051/mmnp/20138202
Angstmann CN, Erickson AM, Henry BI, Mcgann AV, Murray JM, Nichols JA (2017) Fractional order compartment models. SIAM J Appl Math 77:430–446. https://doi.org/10.1137/16M1069249
Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153:198–205. https://doi.org/10.1016/j.jconrel.2011.06.001
Ballou B, Ernst LA, Andreko S, Harper T, Fitzpatrick JA, Waggoner AS, Bruchez MP (2007) Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem 18:389–396. https://doi.org/10.1021/bc060261j
Barbolosi D, Iliadis A (2001) Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK–PD model. Comput Biol Med 31:157–172. https://doi.org/10.1016/S0010-4825(00)00032-9
Belair J, Mackey MC, Mahaffy JM (1995) Age-structured and two-delay models for erythropoiesis. Math Biosci 128:317–346. https://doi.org/10.1016/0025-5564(94)00078-E
Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JM, Hlatky L, Hahnfeldt P (2014) Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol 10:e1003800. https://doi.org/10.1371/journal.pcbi.1003800
Bissery MC, Vrignaud P, Lavelle F, Chabot GG (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7:437–460. https://doi.org/10.1097/00001813-199606000-00010
Bouillon TW, Bruhn J, Radulescu L, Andresen C, Shafer TJ, Cohane C, Shafer SL (2004) Pharmacodynamic interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. Anesthesiology 100:1353–1372. https://doi.org/10.1097/00000542-200406000-00006
Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659. https://doi.org/10.1016/j.addr.2004.02.014
Bueno L, De Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Troconiz IF (2008) Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142–150. https://doi.org/10.1016/j.ejca.2007.10.008
Byun JH, Jung IH (2019) Modeling to capture bystander-killing effect by released payload in target positive tumor cells. BMC Cancer 19:194. https://doi.org/10.1186/s12885-019-5336-7
Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711–723. https://doi.org/10.1007/s10928-012-9280-2
Chang C, Byon W, Lu Y, Jacobsen LK, Badura LL, Sawant-Basak A, Miller E, Liu J, Grimwood S, Wang EQ, Maurer TS (2011) Quantitative PK–PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J 13:565–575. https://doi.org/10.1208/s12248-011-9296-3
Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54:1097–1107. https://doi.org/10.1002/jcph.304
Chen Q, Chen G, Chen J, Shen J, Zhang X, Wang J, Chan A, Gu Z (2019) Bioresponsive protein complex of aPD1 and aCD47 antibodies for enhanced immunotherapy. Nano Lett 19:4879–4889. https://doi.org/10.1021/acs.nanolett.9b00584
Cho M, Cho WS, Choi M, Kim SJ, Han BS, Kim SH, Kim HO, Sheen YY, Jeong J (2009) The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett 189:177–183. https://doi.org/10.1016/j.toxlet.2009.04.017
Choi YH, Han HK (2018) Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig 48:43–60. https://doi.org/10.1007/s40005-017-0370-4
Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165–1170. https://doi.org/10.1038/nbt1340
Dadfar SM, Roemhild K, Drude NI, Von Stillfried S, Knuchel R, Kiessling F, Lammers T (2019) Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 138:302–325. https://doi.org/10.1016/j.addr.2019.01.005
Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–478. https://doi.org/10.1007/BF01061691
Dethlefsen LA, Prewitt JM, Mendelsohn ML (1968) Analysis of tumor growth curves. J Natl Cancer Inst 40:389–405. https://doi.org/10.1093/jnci/40.2.389
Dhandapani R, Sethuraman S, Subramanian A (2019) Nanohybrids-cancer theranostics for tiny tumor clusters. J Control Release 299:21–30. https://doi.org/10.1016/j.jconrel.2019.02.027
Dong D, Wang X, Wang H, Zhang X, Wang Y, Wu B (2015) Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112. Int J Nanomed 10:2521–2535. https://doi.org/10.2147/IJN.S79734
Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151. https://doi.org/10.1016/j.addr.2010.04.009
Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17:2950–2962. https://doi.org/10.1016/j.bmc.2009.02.043
Felmlee MA, Morris ME, Mager DE (2012) Mechanism-based pharmacodynamic modeling. Methods Mol Biol 929:583–600. https://doi.org/10.1007/978-1-62703-050-2_21
Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES (2013) Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia. AAPS J 15:662–673. https://doi.org/10.1208/s12248-013-9480-8
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721. https://doi.org/10.1200/JCO.2002.02.140
Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO (2009) An agonist–antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 85:409–417. https://doi.org/10.1038/clpt.2008.234
Fu LH, Qi C, Hu YR, Lin J, Huang P (2019) Glucose oxidase-instructed multimodal synergistic cancer therapy. Adv Mater 31:e1808325. https://doi.org/10.1002/adma.201808325
Furumoto K, Ogawara K, Yoshida M, Takakura Y, Hashida M, Higaki K, Kimura T (2001) Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. Biochim Biophys Acta 1526:221–226. https://doi.org/10.1016/s0304-4165(01)00132-5
Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419–436. https://doi.org/10.2165/00003088-200342050-00002
Gibbs JP (2010) Prediction of exposure–response relationships to support first-in-human study design. AAPS J 12:750–758. https://doi.org/10.1208/s12248-010-9236-7
Gilkey MJ, Krishnan V, Scheetz L, Jia X, Rajasekaran AK, Dhurjati PS (2015) Physiologically based pharmacokinetic modeling of fluorescently labeled block copolymer nanoparticles for controlled drug delivery in Leukemia therapy. CPT Pharmacomet Syst Pharmacol 4:e00013. https://doi.org/10.1002/psp4.13
Greish K (2012) Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? Drug Discov Today Technol 9:e71–e174. https://doi.org/10.1016/j.ddtec.2011.11.010
Gu Z, Zhu S, Yan L, Zhao F, Zhao Y (2019) Graphene-based smart platforms for combined cancer therapy. Adv Mater 31:e1800662. https://doi.org/10.1002/adma.201800662
Guiot C, Degiorgis PG, Delsanto PP, Gabriele P, Deisboeck TS (2003) Does tumor growth follow a “universal law”? J Theor Biol 225:147–151. https://doi.org/10.1016/s0022-5193(03)00221-2
Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H (2015) Nanoparticle uptake: the phagocyte problem. Nano Today 10:487–510. https://doi.org/10.1016/j.nantod.2015.06.006
Hansen T, Clermont G, Alves A, Eloy R, Brochhausen C, Boutrand JP, Gatti AM, Kirkpatrick CJ (2006) Biological tolerance of different materials in bulk and nanoparticulate form in a rat model: sarcoma development by nanoparticles. J R Soc Interface 3:767–775. https://doi.org/10.1098/rsif.2006.0145
Harashima H, Iida S, Urakami Y, Tsuchihashi M, Kiwada H (1999a) Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J Control Release 61:93–106. https://doi.org/10.1016/S0168-3659(99)00110-8
Harashima H, Tsuchihashi M, Iida S, Doi H, Kiwada H (1999b) Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv Drug Deliv Rev 40:39–61. https://doi.org/10.1016/S0169-409X(99)00039-3
He X, Yin F, Wang D, Xiong LH, Kwok RTK, Gao PF, Zhao Z, Lam JWY, Yong KT, Li Z, Tang BZ (2019) AIE featured inorganic–organic core@shell nanoparticles for high-efficiency siRNA delivery and real-time monitoring. Nano Lett 19:2272–2279. https://doi.org/10.1021/acs.nanolett.8b04677
Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4:806–813. https://doi.org/10.1038/nrc1456
Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, Van Lookeren CM (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124:915–927. https://doi.org/10.1016/j.cell.2005.12.039
Herman AB, Savage VM, West GB (2011) A quantitative theory of solid tumor growth, metabolic rate and vascularization. PLoS ONE 6:e22973. https://doi.org/10.1371/journal.pone.0022973
Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, Lee E, Kolinsky K, Tannu S, Adames V, Garrido R, Linn M, Meille C, Heimbrook D, Vassilev L, Packman K (2014) Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res 20:3742–3752. https://doi.org/10.1158/1078-0432.CCR-14-0460
Hong SH, Choi Y (2018) Mesoporous silica-based nanoplatforms for the delivery of photodynamic therapy agents. J Pharm Investig 48:3–17. https://doi.org/10.1007/s40005-017-0356-2
Hoshyar N, Gray S, Han H, Bao G (2016) The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11:673–692. https://doi.org/10.2217/nnm.16.5
Hwang HS, Shin H, Han J, Na K (2018) Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. J Pharm Investig 48:143–151. https://doi.org/10.1007/s40005-017-0377-x
Jeon G, Ko YT (2019) Enhanced photodyamic therapy via photosensitizer-loaded nanoparticles for cancer treatment. J Pharm Investig 49:1–8. https://doi.org/10.1007/s40005-017-0363-3
Jones H, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol 2:e63. https://doi.org/10.1038/psp.2013.41
Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J (2010) Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 37:221–242. https://doi.org/10.1007/s10928-010-9156-2
Jusko WJ (1973) A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J Pharmacokinet Biopharm 1:175–200. https://doi.org/10.1007/bf01062346
Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186–192. https://doi.org/10.1016/j.tips.2004.02.012
Kim KT, Lee JY, Kim DD, Yoon IS, Cho HJ (2019) Recent progress in the development of poly(lactic-co-glycolic acid)-based nanostructures for cancer imaging and therapy. Pharmaceutics 11:E280. https://doi.org/10.3390/pharmaceutics11060280
Kogame A, Tagawa Y, Shibata S, Tojo H, Miyamoto M, Tohyama K, Kondo T, Prakash S, Shyu WC, Asahi S (2013) Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. Drug Metab Dispos 41:727–734. https://doi.org/10.1124/dmd.112.049650
Krzyzanski W (2015) Pharmacodynamic models of age-structured cell populations. J Pharmacokinet Pharmacodyn 42:573–589. https://doi.org/10.1007/s10928-015-9446-9
Lai SK, Wang YY, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61:158–171. https://doi.org/10.1016/j.addr.2008.11.002
Laird AK (1964) Dynamics of tumor growth. Br J Cancer 18:490–502. https://doi.org/10.1038/bjc.1964.55
Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–187. https://doi.org/10.1016/j.jconrel.2011.09.063
Le QV, Choi J, Oh YK (2018) Nano delivery systems and cancer immunotherapy. J Pharm Investig 48:527–539. https://doi.org/10.1007/s40005-018-0399-z
Lee MK (2019) Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin. J Pharm Investig 49:203–214. https://doi.org/10.1007/s40005-018-0398-0
Lee SY, Cho HJ (2018) An alpha-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy. Drug Deliv 25:738–749. https://doi.org/10.1080/10717544.2018.1446476
Lee SY, Cho HJ (2019) Mitochondria targeting and destabilizing hyaluronic acid derivative-based nanoparticles for the delivery of lapatinib to triple-negative breast cancer. Biomacromol 20:835–845. https://doi.org/10.1021/acs.biomac.8b01449
Lee SY, Ko SH, Shim JS, Kim DD, Cho HJ (2018) Tumor targeting and lipid rafts disrupting hyaluronic acid-cyclodextrin-based nanoassembled structure for cancer therapy. ACS Appl Mater Interfaces 10:36628–36640. https://doi.org/10.1021/acsami.8b08243
Lee YW, Luther DC, Kretzmann JA, Burden A, Jeon T, Zhai S, Rotello VM (2019) Protein delivery into the cell cytosol using non-viral nanocarriers. Theranostics 9:3280–3292. https://doi.org/10.7150/thno.34412
Lees P, Cunningham FM, Elliott J (2004) Principles of pharmacodynamics and their applications in veterinary pharmacology. J Vet Pharmacol Ther 27:397–414. https://doi.org/10.1111/j.1365-2885.2004.00620.x
Levy G (1964) Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342–343. https://doi.org/10.1002/jps.2600530325
Li M, Al-Jamal KT, Kostarelos K, Reineke J (2010) Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4:6303–6317. https://doi.org/10.1021/nn1018818
Li M, Zou P, Tyner K, Lee S (2017) Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical nanoparticles. AAPS J 19:26–42. https://doi.org/10.1208/s12248-016-0010-3
Liu J, Yu M, Zhou C, Zheng J (2013) Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Mater Today 16:477–486. https://doi.org/10.1016/j.mattod.2013.11.003
Lobo ED, Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSciTech 4:E42. https://doi.org/10.1208/ps040442
Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3:703–717. https://doi.org/10.2217/17435889.3.5.703
Luo D, Carter KA, EaG M, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF (2019) Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release 297:39–47. https://doi.org/10.1016/j.jconrel.2019.01.030
Macheras P, Iliadis A (2006) Modeling in biopharmaceutics, pharmacokinetics, and pharmacodynamics. Interdiscip Appl Math 30:3–14. https://doi.org/10.1007/978-3-319-27598-7
Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21:797–802. https://doi.org/10.1021/bc100070g
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
Mager DE, Mody V, Xu C, Forrest A, Lesniak WG, Nigavekar SS, Kariapper MT, Minc L, Khan MK, Balogh LP (2012) Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition. Pharm Res 29:2534–2542. https://doi.org/10.1007/s11095-012-0784-7
Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G (2006) A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math Biosci 200:127–151. https://doi.org/10.1016/j.mbs.2005.12.028
Mahmoudi M, Bertrand N, Zope H, Farokhzad OC (2016) Emerging understanding of the protein corona at the nano-bio interfaces. Nano Today 11:817–832. https://doi.org/10.1016/j.nantod.2016.10.005
Mebius RE, Kraal G (2005) Structure and function of the spleen. Nat Rev Immunol 5:606–616. https://doi.org/10.1038/nri1669
Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511–521. https://doi.org/10.1016/S0009-9236(98)90134-5
Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft ML (2016) Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75:295–304. https://doi.org/10.1016/j.biomaterials.2015.10.019
M'Kendrick AG (1925) Applications of mathematics to medical problems. Proc Edinb Math Soc 44:98–130. https://doi.org/10.1017/S0013091500034428
Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318
Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311–330. https://doi.org/10.1096/fj.04-2747rev
Moghimi SM, Hunter AC, Andresen TL (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 52:481–503. https://doi.org/10.1146/annurev-pharmtox-010611-134623
Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development—Part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol 2:e38. https://doi.org/10.1038/psp.2013.14
Murphy H, Jaafari H, Dobrovolny HM (2016) Differences in predictions of ODE models of tumor growth: a cautionary example. BMC Cancer 16:163. https://doi.org/10.1186/s12885-016-2164-x
Nagashima R, O’Reilly RA, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10:22–35. https://doi.org/10.1002/cpt196910122
Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883–908. https://doi.org/10.2165/00003088-200342100-00002
Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235–249. https://doi.org/10.1517/17425255.3.2.235
Nichols JW, Bae YH (2014) EPR: evidence and fallacy. J Control Release 190:451–464. https://doi.org/10.1016/j.jconrel.2014.03.057
Nieuwenhuijs DJ, Olofsen E, Romberg RR, Sarton E, Ward D, Engbers F, Vuyk J, Mooren R, Teppema LJ, Dahan A (2003) Response surface modeling of remifentanil–propofol interaction on cardiorespiratory control and bispectral index. Anesthesiology 98:312–322. https://doi.org/10.1097/00000542-200302000-00008
Norton L, Simon R (1977) Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 58:1735–1741. https://doi.org/10.1093/jnci/58.6.1735
Ohlson M, Sorensson J, Haraldsson B (2001) A gel-membrane model of glomerular charge and size selectivity in series. Am J Physiol Ren Physiol 280:F396–F405. https://doi.org/10.1152/ajprenal.2001.280.3.F396
Ollikainen E, Liu D, Kallio A, Makila E, Zhang H, Salonen J, Santos HA, Sikanen TM (2017) The impact of porous silicon nanoparticles on human cytochrome P450 metabolism in human liver microsomes in vitro. Eur J Pharm Sci 104:124–132. https://doi.org/10.1016/j.ejps.2017.03.039
Opitz AW, Wickstrom E, Thakur ML, Wagner NJ (2010) Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determined in tumor-bearing mice. Oligonucleotides 20:117–125. https://doi.org/10.1089/oli.2009.0216
Panetta JC (1997) A mathematical model of breast and ovarian cancer treated with paclitaxel. Math Biosci 146:89–113. https://doi.org/10.1016/S0025-5564(97)00077-1
Pereira P, Barreira M, Queiroz JA, Veiga F, Sousa F, Figueiras A (2017) Smart micelleplexes as a new therapeutic approach for RNA delivery. Expert Opin Drug Deliv 14:353–371. https://doi.org/10.1080/17425247.2016.1214567
Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM (2017) Mediating passive tumor accumulation through particle size, tumor type, and location. Nano Lett 17:2879–2886. https://doi.org/10.1021/acs.nanolett.7b00021
Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9:615–627. https://doi.org/10.1038/nrd2591
Piao X, Yin H, Guo S, Wang H, Guo P (2019) RNA nanotechnology to solubilize hydrophobic antitumor drug for targeted delivery. Adv Sci 6:1900951. https://doi.org/10.1002/advs.201900951
Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D, Rautou PE (2017) Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol 66:212–227. https://doi.org/10.1016/j.jhep.2016.07.009
Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412–2417. https://doi.org/10.1158/0008-5472.CAN-12-4561
Qian X, Zhang J, Gu Z, Chen Y (2019) Nanocatalysts-augmented Fenton chemical reaction for nanocatalytic tumor therapy. Biomaterials 211:1–13. https://doi.org/10.1016/j.biomaterials.2019.04.023
Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–796. https://doi.org/10.1038/nrd1494
Ravindran S, Suthar JK, Rokade R, Deshpande P, Singh P, Pratinidhi A, Khambadkhar R, Utekar S (2018) Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Curr Drug Metab 19:327–334. https://doi.org/10.2174/1389200219666180305154119
Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G (2011) A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer 47:479–490. https://doi.org/10.1016/j.ejca.2010.10.003
Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862–1868. https://doi.org/10.1016/j.ejca.2007.05.011
Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova K, Deen WM, Scheinberg DA, Mcdevitt MR (2010) Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci USA 107:12369–12374. https://doi.org/10.1073/pnas.0913667107
Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 43:1823–1837. https://doi.org/10.1124/dmd.115.065920
Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, Wallin JJ (2010) Pharmacokinetic–pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1436–1442. https://doi.org/10.1124/dmd.110.032912
Sang W, Zhang Z, Dai Y, Chen X (2019) Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev 48:3771–3810. https://doi.org/10.1039/c8cs00896e
Seaton A, Tran L, Aitken R, Donaldson K (2010) Nanoparticles, human health hazard and regulation. J R Soc Interface 7(Suppl 1):S119–S129. https://doi.org/10.1098/rsif.2009.0252.focus
Shah DK, Haddish-Berhane N, Betts A (2012) Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 39:643–659. https://doi.org/10.1007/s10928-012-9276-y
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358–371. https://doi.org/10.1002/cpt1979253358
Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5–24. https://doi.org/10.1016/j.addr.2012.09.004
Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094–1101. https://doi.org/10.1158/0008-5472.CAN-03-2524
Singh AP, Guo L, Verma A, Wong GG, Shah DK (2019) A cell-level systems PK–PD model to characterize in vivo efficacy of ADCs. Pharmaceutics 11:98. https://doi.org/10.3390/pharmaceutics11020098
Soininen SK, Vellonen KS, Heikkinen AT, Auriola S, Ranta VP, Urtti A, Ruponen M (2016) Intracellular PK/PD relationships of free and liposomal doxorubicin: quantitative analyses and PK/PD modeling. Mol Pharm 13:1358–1365. https://doi.org/10.1021/acs.molpharmaceut.6b00008
Sonavane G, Tomoda K, Makino K (2008) Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B 66:274–280. https://doi.org/10.1016/j.colsurfb.2008.07.004
Spratt JA, Von Fournier D, Spratt JS, Weber EE (1993) Decelerating growth and human breast cancer. Cancer 71:2013–2019. https://doi.org/10.1002/1097-0142(19930315)71:6%3c2013:aid-cncr2820710615%3e3.0.co;2-v
Sudhakar B, Nagajyothi K, Murthy KV (2014) Nanosuspensions as a versatile carrier based drug delivery system—an overview. Curr Drug Deliv 11:299–305. https://doi.org/10.2174/1567201811666140323131342
Sung JH, Dhiman A, Shuler ML (2009) A combined pharmacokinetic–pharmacodynamic (PK–PD) model for tumor growth in the rat with UFT administration. J Pharm Sci 98:1885–1904. https://doi.org/10.1002/jps.21536
Taurin S, Nehoff H, Greish K (2012) Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release 164:265–275. https://doi.org/10.1016/j.jconrel.2012.07.013
Tjorve KMC, Tjorve E (2017) The use of Gompertz models in growth analyses, and new Gompertz-model approach: an addition to the unified-Richards family. PLoS ONE 12:e0178691. https://doi.org/10.1371/journal.pone.0178691
Upton RN, Mould DR (2014) Basic concepts in population modeling, simulation, and model-based drug development: Part 3—introduction to pharmacodynamic modeling methods. CPT Pharmacomet Syst Pharmacol 3:e88. https://doi.org/10.1038/psp.2013.71
Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567–1571
Vasalou C, Helmlinger G, Gomes B (2015) A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS ONE 10:e0118977. https://doi.org/10.1371/journal.pone.0118977
Von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS (2017) Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol 35:159–171. https://doi.org/10.1016/j.tibtech.2016.07.006
Wei Y, Quan L, Zhou C, Zhan Q (2018) Factors relating to the biodistribution & clearance of nanoparticles & their effects on in vivo application. Nanomedicine 13:1495–1512. https://doi.org/10.2217/nnm-2018-0040
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WC (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:16014. https://doi.org/10.1038/natrevmats.2016.14
Wisse E, Jacobs F, Topal B, Frederik P, De Geest B (2008) The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 15:1193–1199. https://doi.org/10.1038/gt.2008.60
Wong H, Choo EF, Alicke B, Ding X, La H, Mcnamara E, Theil FP, Tibbitts J, Friedman LS, Hop CE, Gould SE (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846–3855. https://doi.org/10.1158/1078-0432.CCR-12-0738
Xiang H, Chen Y (2019) Energy-converting nanomedicine. Small 15:e1805339. https://doi.org/10.1002/smll.201805339
Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T (2008) Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267–1274. https://doi.org/10.1124/dmd.107.019711
Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P (2015) Mechanistic understanding of translational pharmacokinetic–pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. Drug Metab Dispos 43:54–62. https://doi.org/10.1124/dmd.114.061143
Yang RS, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK, Yang CS, Lin P (2007) Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect 115:1339–1343. https://doi.org/10.1289/ehp.10290
Yang J, Mager DE, Straubinger RM (2010) Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 12:1–10. https://doi.org/10.1208/s12248-009-9155-7
Yoon SW, Shin DH, Kim JS (2019) Liposomal itraconazole formulation for the treatment of glioblastoma using inclusion complex with HP-β-CD. J Pharm Investig 49:477–483. https://doi.org/10.1007/s40005-019-00432-4
Yoshida K, Budha N, Jin JY (2017) Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology. Clin Pharmacol Ther 101:597–602. https://doi.org/10.1002/cpt.622
Yuan D, He H, Wu Y, Fan J, Cao Y (2019) Physiologically based pharmacokinetic modeling of nanoparticles. J Pharm Sci 108:58–72. https://doi.org/10.1016/j.xphs.2018.10.037
Zamboni WC, D’Argenio DZ, Stewart CF, Macvittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7:2301–2308
Zhang YN, Poon W, Tavares AJ, Mcgilvray ID, Chan WCW (2016) Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J Control Release 240:332–348. https://doi.org/10.1016/j.jconrel.2016.01.020
Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, Zannikou M, Lopez-Rosas A, Han Y, Xiao T, Pituch KC, Kanojia D, Balyasnikova IV, Lesniak MS (2019) Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc Natl Acad Sci USA 116:23714–23723. https://doi.org/10.1073/pnas.1906346116
Zhao P, Rowland M, Huang SM (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17–20. https://doi.org/10.1038/clpt.2012.68
Acknowledgements
This research was supported by the National Research Foundation of Korea (NRF) Grants funded by the Korea Government (MSIT) (NRF-2019R1A2C2007249).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors have declared no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Byun, J.H., Han, DG., Cho, HJ. et al. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. Arch. Pharm. Res. 43, 80–99 (2020). https://doi.org/10.1007/s12272-020-01209-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01209-2